Compare ODC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | PGEN |
|---|---|---|
| Founded | 1941 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1994 | 2013 |
| Metric | ODC | PGEN |
|---|---|---|
| Price | $90.41 | $6.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 117.5K | ★ 5.2M |
| Earning Date | 06-04-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 50.45 | N/A |
| EPS | ★ 1.69 | 0.03 |
| Revenue | ★ $485,572,000.00 | $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | ★ $51.98 | $215.33 |
| Revenue Growth | ★ 10.97 | N/A |
| 52 Week Low | $45.61 | $2.62 |
| 52 Week High | $107.00 | $7.32 |
| Indicator | ODC | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 52.22 |
| Support Level | $70.50 | $3.44 |
| Resistance Level | $105.72 | N/A |
| Average True Range (ATR) | 3.80 | 0.42 |
| MACD | -1.25 | -0.02 |
| Stochastic Oscillator | 23.50 | 45.85 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.